Mariana Chavez-MacGregor, MD, MSc, on Adjuvant Endocrine Therapy and Everolimus in HR-Positive, HER2-Negative Breast Cancer
2022 San Antonio Breast Cancer Symposium
Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the SWOG S1207 trial which was designed to evaluate the role of adjuvant everolimus in combination with adjuvant endocrine therapy among patients with high-risk, hormone receptor–positive, HER2-negative early-stage breast cancer. Adding everolimus did not improve invasive disease–free or overall survival and was associated with high rates of adverse events (Abstract GS1-07).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
SWOG 1207, it's a large phase III randomized control clinical trial evaluating the addition of one year of adjuvant everolimus to adjuvant endocrine therapy for the patients with high-risk forms of hormone receptor-positive, HER2-negative breast cancer.
The rationale behind the study are the results that we'll know about the BOLERO-2 trial. BOLERO-2, it's a clinical trial that use everolimus, an mTOR inhibitor, and confirmed that the use of this drug in combination with exemestane improved progression-free survival compared to exemestane alone in patients with metastatic disease. Therefore, it was very important for us to evaluate whether everolimus, in combination with endocrine therapy used in the early stage setting, could improve outcomes for our patients.
The trial, it's a cooperative group trial that enrolled patients across the nation, and we enrolled a total of 1,939 patients. Patients were randomized one-to-one to receive adjuvant endocrine therapy, physician's choice, with everolimus given at a dose of 10 milligrams daily or matched placebo.
We, in the trial, tried to identify high-risk patients. Therefore, the eligibility criteria really tried to reflect on this. Patients that underwent surgery first and had lymph node-negative tumors were eligible if they had tumors larger than two centimeters or using MammaPrint or Oncotype, had high-risk tumors. Those with one to three positive lymph nodes also needed to have high-risk MammaPrint or recurrent score greater than 25 for grade 3 tumors. All patients with four or more positive lymph nodes were eligible. Patients that received neoadjuvant chemotherapy upfront were eligible if at the time of surgery they had one or more lymph nodes involved. So it's very important to emphasize that this is a high-risk population. All the patients in the trial receive chemotherapy, either neo or adjuvant.
Once we remove ineligible patients, we had 896 patients in each arm. The arms were well balanced. The patient population with a median age of 54 years old. 32% of the patients were premenopausal.
The main endpoint of the study was the invasive disease-free survival, and what we observed is that this is a negative study. The addition of adjuvant everolimus did not improve invasive disease-free survival in our patients. We look at overall survival, and we also observed no differences in overall survival according to treatment arms.
We, however, in exploratory analysis, observe a difference in the result according to treatment arm amongst the 571 premenopausal patients. In premenopausal patients, we saw a statistically significant improvement in invasive disease-free survival and overall survival. And we think that this observation is clearly thought-provoking and hypothesis-generating.
Some other things that are important to mention about the trial is that it was associated with a high discontinuation rate. The discontinuation rate was slightly above 50% in the everolimus arm and in most of the patients it was associated to grade 3 or 4 adverse events.
In conclusion, the study was a negative trial for the primary endpoint. We do find incredibly interesting the observation among premenopausal patients.
There are next steps as part of our study. We're going to further explore the clinical findings in the premenopausal patients. And we have a team of incredible scientists that are going to be leading very interesting translational studies that are hopefully going to give us more information about what is happening, not only in the premenopausal population, but in the entire cohort, and reveal information that hopefully is relevant, not only for drugs that block this pathway, but hopefully revealing of important mechanisms of endocrine resistance.
Related Videos
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant (Abstract GS3-04).
The ASCO Post Staff
Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for low levels of participation and advocates for capturing the experience of patients not represented in traditional clinical trials, so real-world data can address these validity deficits.
The ASCO Post Staff
Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, discusses phase III findings showing that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences from noninvasive breast cancer after a median of 7 years from treatment cessation. Babytam at 5 mg/d for 3 years significantly lowered recurrence from noninvasive breast cancer at 10 years without “excess” adverse events (Abstract GS4-08).
The ASCO Post Staff
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the phase III EMERALD trial, the first study to demonstrate improved progression-free survival vs standard of care in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer with one to two prior lines of endocrine treatment, with or without one line of chemotherapy. This finding applied to all patients in the study, including the subgroup with ESR1 mutations (Abstract GS3-01).
The ASCO Post Staff
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study found that 74% of women had at least one pregnancy, most (70%) within 2 years. Birth defects were low (2%) and were not clearly associated with treatment exposure. Dr. Partridge explains that these data stress the need to incorporate patient-centered reproductive health care in the treatment and follow-up of young women with breast cancer (Abstract GS4-09).
